Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

OBJECTIVE: To describe a new systemic lupus erythematosus (SLE) Responder Index (SRI) based on the belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. METHODS: Data from a 449-patient randomized, double-blind, placebo-controlled study of 3 doses of belimumab (1...

Full description

Saved in:
Bibliographic Details
Main Authors: Furie, Richard A., Petri, Michelle A., Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Stohl, William, Chatham, W. Winn, Strand, Vibeke, Weinstein, Arthur, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748175/
https://ncbi.nlm.nih.gov/pubmed/19714615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24698
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items